Yat Sun Or
2016
In 2016, Yat Sun Or earned a total compensation of $1.3M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 22% decrease compared to previous year.
Compensation breakdown
Bonus | $114,633 |
---|---|
Non-Equity Incentive Plan | $48,078 |
Option Awards | $654,806 |
Salary | $386,069 |
Stock Awards | $122,428 |
Other | $15,857 |
Total | $1,341,871 |
Or received $654.8K in option awards, accounting for 49% of the total pay in 2016.
Or also received $114.6K in bonus, $48.1K in non-equity incentive plan, $386.1K in salary, $122.4K in stock awards and $15.9K in other compensation.
Rankings
In 2016, Yat Sun Or's compensation ranked 6,797th out of 14,075 executives tracked by ExecPay. In other words, Or earned more than 51.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,797 | 52nd |
Manufacturing | 2,537 | 54th |
Chemicals And Allied Products | 827 | 57th |
Drugs | 636 | 59th |
Pharmaceutical Preparations | 502 | 57th |
Or's colleagues
We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2016.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019